Aminoglycosides and renal magnesium homeostasis in humans

Details

Serval ID
serval:BIB_8A51ADAE620F
Type
Article: article from journal or magazin.
Collection
Publications
Title
Aminoglycosides and renal magnesium homeostasis in humans
Journal
Nephrology, Dialysis, Transplantation
Author(s)
von Vigier  R. O., Truttmann  A. C., Zindler-Schmocker  K., Bettinelli  A., Aebischer  C. C., Wermuth  B., Bianchetti  M. G.
ISSN
0931-0509 (Print)
Publication state
Published
Issued date
06/2000
Volume
15
Number
6
Pages
822-6
Notes
Journal Article --- Old month value: Jun
Abstract
BACKGROUND: The use of aminoglycosides has been linked with hypomagnesaemia in scattered reports. The objective of the study was to measure prospectively the effect of treatment with the aminoglycoside amikacin on renal magnesium homeostasis. METHODS: Twenty-four cystic fibrosis patients (aged 9-19 years) admitted because of exacerbation of pulmonary symptoms caused by Pseudomonas aeruginosa were treated with the aminoglycoside amikacin and the cephalosporin ceftazidime for 14 days. Renal values and plasma and urinary electrolytes were measured before and at the end of the systemic anti-pseudomonal therapy. RESULTS: In the patients with cystic fibrosis, treatment with amikacin and ceftazidime did not modify plasma creatinine or urea and plasma or urinary sodium, potassium and calcium. Treatment with amikacin and ceftazidime significantly decreased both plasma total magnesium (from 0.77 (0. 74-0.81) to 0.73 (0.71-75) mmol/l; median and interquartile range) and ionized magnesium (from 0.53 (0.50-0.55) to 0.50 (0.47-0.52) mmol/l) concentration and increased fractional urinary magnesium excretion (from 0.0568 (0.0494-0.0716) to 0.0721 (0.0630-0.111)) and total urinary magnesium excretion (from 30.7 (26.5-38.0) to 38.5 (31. 5-49.0) micromol/l glomerular filtration rate). CONCLUSIONS: The present study demonstrates that systemic therapy with amikacin plus ceftazidime causes mild hypomagnesaemia secondary to renal magnesium wasting even in the absence of a significant rise in circulating creatinine and urea.
Keywords
Adolescent Amikacin/therapeutic use Anti-Bacterial Agents/*therapeutic use Ceftazidime/therapeutic use Cephalosporins/therapeutic use Child Cystic Fibrosis/complications/*metabolism Drug Therapy, Combination/*therapeutic use Electrolytes/blood/urine Female Homeostasis Humans Kidney/drug effects/*metabolism Lung Diseases/complications/*drug therapy/microbiology Magnesium/*metabolism Male Pseudomonas Infections/complications/*drug therapy Pseudomonas aeruginosa
Pubmed
Web of science
Open Access
Yes
Create date
28/01/2008 13:50
Last modification date
20/08/2019 14:49
Usage data